Director at Revelation Biosciences (REVB) has 2,261 shares sold for taxes

Rhea-AI Filing Summary

Revelation Biosciences director Lakhmir S. Chawla had 2,261 common shares sold on February 3, 2026 to cover taxes on vesting restricted stock. The issuer sold the shares on the director’s behalf at a weighted average price of $1.85 per share.

After this mandatory tax-withholding transaction, Chawla beneficially owned 12,158 common shares directly. All share figures reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chawla Lakhmir S

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,261	$1.85	$4K

Holdings After Transaction: Common Stock — 12,158 shares (Direct)

Footnotes (1)

1. All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chawla Lakhmir S

(Last) (First) (Middle)

4660 LA JOLLA VILLAGE DR

SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		F		2,261(1)(2)	D	$1.85(3)	12,158(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

2. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ J.P. Galda, as attorney-in-fact for Lakhmir S Chawla	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did REVB director Lakhmir S. Chawla report?

Director Lakhmir S. Chawla reported a Form 4 transaction where 2,261 Revelation Biosciences common shares were sold on his behalf. The sale covered tax obligations from vesting restricted stock awards and was coded as an F transaction, indicating tax-related share withholding.

At what price were the 2,261 REVB shares sold for taxes?

The 2,261 shares were sold at a weighted average price of $1.85 per share. The filing notes individual trades occurred in a range from $1.84 to $1.87, and detailed trade breakdowns are available to shareholders or regulators upon request.

How many REVB shares does the director own after this Form 4?

Following the reported transaction, director Lakhmir S. Chawla beneficially owned 12,158 shares of Revelation Biosciences common stock directly. These remaining shares are after the 2,261-share tax sale executed by the issuer on his behalf on February 3, 2026.

Was the REVB insider share sale a discretionary transaction?

No. The filing states the shares were sold by the issuer solely to satisfy required tax obligations when restricted stock vested. It describes the sale as mandatory, and notes the reporting person did not exercise investment discretion regarding the decision to sell these shares.

How did the reverse stock split affect the REVB share numbers reported?

All share counts in the Form 4 reflect a 1-for-4 reverse stock split effective January 28, 2026. This means previous holdings and the 2,261 shares sold for taxes are already adjusted to the post-split basis, ensuring consistency with the company’s current share structure.

What does transaction code F mean in the REVB Form 4 filing?

Transaction code F indicates a tax-related transaction where shares are withheld or sold to cover tax obligations tied to equity awards. In this case, the issuer sold 2,261 shares on behalf of director Lakhmir S. Chawla upon vesting of restricted stock awards to meet required tax liabilities.